Marksans Pharma Limited has informed the Exchange regarding Proceedings of 33rd Annual General Meeting held on August 08, 2025
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma held its 33rd Annual General Meeting on August 8, 2025, via video conferencing from 9:00 AM to 9:40 AM, chaired by Mr. Mark Saldanha. All resolutions were approved by members with the requisite majority. Key items included adoption of audited standalone and consolidated financial statements for FY ending March 31, 2025, and declaration of a dividend of Rs. 0.80 (80%) per equity share of Re. 1 face value. The meeting also approved the appointment of Mr. Srinivas Mishra as Independent Director for five years, re-appointment of Mr. Mark Saldanha as Managing Director for five years from October 6, 2025, and amendments to the Marksans ESOP Scheme 2024 including extending stock options to subsidiary employees. Mrs. Sandra Saldana was re-appointed as a director retiring by rotation, and M/s Jinesh Dedhia & Associates was appointed as secretarial auditor for five years. Voting results will be announced by August 9, 2025.
Routine AGM proceedings with all resolutions passing; the confirmed Rs. 0.80 per share dividend and re-appointment of the Managing Director are positive governance signals for shareholders, while the expanded ESOP scheme may lead to some dilution over time.